Xenon Pharmaceuticals (NASDAQ: XENE) insider transactions
In the twelve months to 10 November 2026, executives and directors of Xenon Pharmaceuticals reported 26 open-market sales of 381,589 shares ($22.0m) and 2 open-market purchases of 45,000 shares ($1.7m), by 7 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 15 October 2026 | Kelly Thomas Patrick | Chief Financial Officer | Option exercise | +7,500 | — | 22,500 | Form 4 |
| 30 September 2026 | Mortimer Ian | President & CEO | Open-market purchase | +30,000 | $37.38 | 49,923 | Form 4 |
| 30 September 2026 | Kelly Thomas Patrick | Chief Financial Officer | Open-market purchase | +15,000 | $37.32 | 15,000 | Form 4 |
| 1 September 2026 | Svoronos Dawn | Director | Option exercise | +5,144 | $8.15 | 31,373 | Form 4 |
| 28 August 2026 | Kenney Christopher John | Chief Medical Officer | Open-market sale | −6,368 | $60.17 | 702 | Form 4 |
| 28 August 2026 | Kenney Christopher John | Chief Medical Officer | Open-market sale | −700 | $60.98 | 2 | Form 4 |
| 11 August 2026 | Gannon Steven | Director | Open-market sale | −10,000 | $64.06 | 1,870 | Form 4 |
| 5 June 2026 | Cannon Gillian | Director | Open-market sale | −1,190 | $53.14 | 1,455 | Form 4 |
| 5 June 2026 | Patou Gary | Director | Open-market sale | −1,322 | $53.14 | 24,896 | Form 4 |
| 1 June 2026 | Svoronos Dawn | Director | Option exercise | +2,645 | — | 27,645 | Form 4 |
| 1 June 2026 | Svoronos Dawn | Director | Shares withheld for tax | −1,416 | $53.41 | 26,229 | Form 4 |
| 1 June 2026 | Cannon Gillian | Director | Option exercise | +2,645 | — | 2,645 | Form 4 |
| 1 June 2026 | Gannon Steven | Director | Option exercise | +2,645 | — | 13,286 | Form 4 |
| 1 June 2026 | Gannon Steven | Director | Shares withheld for tax | −1,416 | $53.41 | 11,870 | Form 4 |
| 1 June 2026 | Garofalo Elizabeth A. | Director | Option exercise | +2,645 | — | 2,645 | Form 4 |
| 1 June 2026 | Gover Justin D. | Director | Option exercise | +2,645 | — | 2,645 | Form 4 |
| 1 June 2026 | Machado Patrick | Director | Option exercise | +2,645 | — | 2,645 | Form 4 |
| 1 June 2026 | Patou Gary | Director | Option exercise | +2,645 | — | 26,218 | Form 4 |
| 12 May 2026 | Gannon Steven | Director | Option exercise | +3,500 | $7.38 | 10,641 | Form 4 |
| 13 March 2026 | Mortimer Ian | President & CEO | Open-market sale | −7,308 | $55.23 | 19,923 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Xenon Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.